Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
10 févr. 2014 07h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...